Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:35:19.641Z.
Calculation as of: 2026-10-06T13:35:19.641Z.
Quote observation: 2026-10-06T13:30:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8c4723d74b6f0443862f85907ca9030ea6941843cb736177163438a313e1ca1
PE RATIO
N/A
Market Cap
$138.72M
PE Ratio
N/A
TTM Avg
1879.79
3Y Avg
1257.96
5Y Avg
875.52
Market Cap
$136.86M
PE Ratio
N/A
TTM Avg
194.70
3Y Avg
73.96
5Y Avg
73.96
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Cognition Inc (ACOG) | $142.11M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 6.75 | 6.25 | 6.25 | 6.25 |
| Korsana Biosciences, Inc. (KRSA)vs › | $143.81M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.72M | N/A | 1879.79 | 1257.96 | 875.52 |
| AirSculpt Technologies, Inc. (AIRS)vs › | $136.86M | N/A | 194.70 | 73.96 | 73.96 |
| Freenome, Inc. (FRNM)vs › | $137.20M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $147.02M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $150.59M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $133.00M | N/A | 18.93 | 18.93 | 18.93 |
| Entera Bio Ltd. (ENTX)vs › | $131.11M | N/A | 2.13 | 2.46 | 2.46 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
